Clinical trial
EValuate Ibrutinib Retention iN Chronic Lymphocytic Leukemia Patients Treated in a rEal World Setting - EVIdeNCE
NCT03720561 is registered in ClinicalTrials.gov with Janssen-Cilag S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EValuate Ibrutinib Retention iN Chronic Lymphocytic Leukemia Patients Treated in a rEal World Setting - EVIdeNCE
- Lead sponsor
- Janssen-Cilag S.p.A.
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 30, 2018
- Completion date
- November 12, 2021
- Enrollment
- 312 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.